APA (7th ed.) Citation

CT, T., HS, K., MF, M., & LA, R. (2014). Cost-Minimization Analysis of Bevacizumab Verse Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer in Kras Wild-Type Patients in the Supplementary Health Care System in Brazil. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A641. https://doi.org/10.1016/j.jval.2014.08.2311

Chicago Style (17th ed.) Citation

CT, Tsuchiya, Kim HS, Maximo MF, and Ramos LA. "Cost-Minimization Analysis of Bevacizumab Verse Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer in Kras Wild-Type Patients in the Supplementary Health Care System in Brazil." Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 17, no. 7 (2014): A641. https://doi.org/10.1016/j.jval.2014.08.2311.

MLA (9th ed.) Citation

CT, Tsuchiya, et al. "Cost-Minimization Analysis of Bevacizumab Verse Cetuximab in First-Line Treatment for Metastatic Colorectal Cancer in Kras Wild-Type Patients in the Supplementary Health Care System in Brazil." Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 17, no. 7, 2014, p. A641, https://doi.org/10.1016/j.jval.2014.08.2311.